Pharmacopsychiatry 2024; 57(02): 93
DOI: 10.1055/s-0044-1779580
Abstracts │ XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Poster Abstracts

Fluvoxamine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring (TDM) trial

TDM-VIGIL Konsortium
R. Taurines
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
,
G. Kunkel
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
,
S. Fekete
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
,
M. Gerlach
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
,
M. Romanos
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
,
K. Egberts
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
› Author Affiliations
 

The selective serotonin reuptake inhibitor fluvoxamine is used on- and off-label in the treatment of children and adolescents with psychiatric disorders. To investigate the relationship between fluvoxamine dose, serum concentration and clinical outcomes in daily clinical practice, and to validate a therapeutic reference range (TRR) in pediatric patients, multicenter prospective and observational study data were analyzed.

Steady state through serum concentrations of fluvoxamine were measured in pediatric patients as part of a therapeutic drug monitoring service (n=60) and within the TDM-VIGIL pharmacovigilance trial2 (n=10). Patient characteristics, doses, serum concentrations, and therapeutic outcomes were assessed by standardized measures.

Seventy children and adolescents (54.3% female, mean age 14.8 years), 55.2% diagnosed with obsessive compulsive disorder (OCD) were included. A positive correlation between daily dose and fluvoxamine concentrations was found (rs= 0.34, p= 0.004). Gender, age, and concomitant medications had no significant effect on fluvoxamine concentrations. Using a rough estimation-method considering only responders to fluvoxamine, we estimated a transdiagnostic TRR for minors of 40-240 ng/ml (comparable to the TRR of adults 60-230ng/ml), which might be higher for patients with OCD (55-300ng/ml).

Our preliminary results may contribute to a TRR of fluvoxamine in children and adolescents and further establish TDM in child and adolescent psychiatry.



Publication History

Article published online:
12 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany